[Broad cardiorenal protection with SGLT2 inhibitors : Evidence, indications and clinical practice]
{{output}}
Background: Sodium-glucose cotransporter‑2 (SGLT2) inhibitors were developed as glucose-lowering drugs but provide robust cardiorenal protection in large outcome trials, including in people without diabetes. ... ...
